| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H25NO4 |
| Molecular Weight | 355.4275 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12OC3=C4C(C[C@H]5N(CC=C(C)C)CC[C@@]14[C@@]5(O)CCC2=O)=CC=C3O
InChI
InChIKey=OHKCLOQPSLQCQR-MBPVOVBZSA-N
InChI=1S/C21H25NO4/c1-12(2)6-9-22-10-8-20-17-13-3-4-14(23)18(17)26-19(20)15(24)5-7-21(20,25)16(22)11-13/h3-4,6,16,19,23,25H,5,7-11H2,1-2H3/t16-,19+,20+,21-/m1/s1
| Molecular Formula | C21H25NO4 |
| Molecular Weight | 355.4275 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Nalmexone is an opioid partial agonist or mixed agonist-antagonist with both analgesic and narcotic antagonist properties. In preclinical models parenteral nalmexone was a moderately active antagonist and therefore might have low abuse potential. At the same time, early work in man indicated analgesic
activity in doses above 20 mg.
Approval Year
PubMed
Sample Use Guides
Doses of 5 mg and 10 mg of morphine were
compared with 15 mg and 30 mg of nalmexone in the first study and with 40 mg and 60 mg of nalmexone in the second one. Each patient was given a "round" of 4 medications, a low and high dose of morphine with a low and high dose of nalmexone, to establish and compare doseeffect curves of the 2 drugs. The medications were prepared in identical ampules and administered intramuscularly under random, double-blind conditions.
Route of Administration:
Intramuscular
